TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01199224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: veliparib formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: veliparib formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: veliparib formulation C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: veliparib formulation C
Study: NCT02529163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late-life Schizophrenia ICP
Description: The ICP medication algorithms first trial begins with:~* Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~* Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~* Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~* Clozapine trial~If subject refuses a Clozapine trial then:~* Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~* Paliperidone~* Risperidone~* Flupentixol~* Aripiprazole~Physicians will be prompted for non-pharmacological interventions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The TAU group will be offered non-pharmacological interventions such as (but not limited to):~* metabolic monitoring~* skin hygiene~* pain management~* nutritional counseling~* family counselling~* Financial/housing support~* Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~* Risperidone~* Aripiprazole~* Quetiapine~* Olanzapine~* Paliperidone~* Clozapine~* Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician.
Study: NCT00389493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Dosage of 0.5 mg to 4.0 mg per day as tolerated

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure/ritual prevention therapy (EX/RP)
Description: EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be identical in appearance to those of risperidone.
Study: NCT00924768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20K EU CCRE
Description: Inhalation of CCRE
Study: NCT04372823

Intervention type: BEHAVIORAL
Intervention: Policy/program
Description: Policy/program to improve nutrition and increase physical activity
Study: NCT01487109

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT02228148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NFS
Description: Cochlear Nucleus Fitting Software

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSS
Description: Cochlear Nucleus Custom SoundTM Suite
Study: NCT01729559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5000 Units unfractionated Heparin Q 8 hr
Description: Venous thromboembolic prophylaxis medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30mg enoxaparin Q12 hr
Description: Venous thromboembolic prophylaxis
Study: NCT01697124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARK-EC
Description: The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
Study: NCT06470126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% NaOCl group: The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.
Description: 10 mL 2.5% NaOCl application followed the mechanical preparation. After 2 mL 0.9% saline application, the second samples were taken by placing a sterile cone in the largest canal of the tooth (distal canal for 60 seconds). The mesiobuccal and distobuccal canals were closed with a sterile cotton pellet while the samples were taken. After the application, the root canal filling was completed with a calcium hydroxide-containing paste (TgPex™, London, England), glass ionomer cement (Ionofil U, Voco, Cuxhaven, Germany) was placed, and the teeth were restored with a Stainless-Steel Crown (3M ESPE, Seefeld, Germany)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.9% sterile saline solution combined with 80 seconds: The OzonyTronX® interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.
Description: The canals were irrigated with 10 mL 0.9% sterile saline. Ozone treatment (OzonyTronX with CA probe) was applied for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with 2.5% NaOCl, and the canal treatment was completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl with 80 seconds OzonyTronX®:The interventions performed in the study are root- canal therapies and disinfection procedure of these therapies.
Description: The disinfection of root canals was done using 10 mL, 2.5% NaOCl, and ozone treatment for 80 seconds, and 2 mL 0.9% saline application was performed. Finally, the second samples were taken by the method described in group with %2.5 NaOCl, and the canal treatment was completed.
Study: NCT04165824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: * An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~* Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks.
Study: NCT04111939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communities That HEAL
Description: The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
Study: NCT00620724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: 20 mg of slow-release Nifedipine three times daily
Study: NCT02804126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP (transversus abdominis plane block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QL (quadratus lumborum block)
Description: ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: In both groups (TAP\&QL) 0.25% bupivacaine will be given (0.2 mL/kg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
Study: NCT04111939

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control
Description: Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.
Study: NCT02804126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: Intravenous metamizol will be used (1.0 gram), up to 4 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
Study: NCT04591158

Intervention type: DEVICE
Group type: OTHER
Intervention: Butterfly iQ
Description: The Butterfly iQ is an ultrasound system that enable diagnostic ultrasound imaging and measurement of anatomical structures and fluids of adult and pediatric patients. It is a non-invasive device and does not impose any health hazards.
Study: NCT02574273

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Secret Agent Society (SAS) Program
Description: The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
Study: NCT04743999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Description: We will evaluate patients' quality of life with a series of questionnaires at baseline, 3, 6, 12, and 24 months after surgical staging. These are prospectively validated questionnaires and include FACT-G (physical and functional well-being sections), FACT-En (additional concerns section), FACT/GOG-NTX-4 (additional concerns section), and FACT-C (items C3 and C5).These sections will be combined into one single form for ease of completion for the patients (a total of 36 items).
Study: NCT01555879

Intervention type: DRUG
Intervention: Abatacept
Description: As prescribed by a doctor for patient medical care.
Study: NCT02350465

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Concentric Exercise
Description: Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
Study: NCT01961050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Focused Brief Physician Intervention (DFBPI)
Description: The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.

Intervention type: OTHER
Group type: OTHER
Intervention: Services as usual
Description: Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
Study: NCT01101633

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alginate
Description: a 500 ml alginate beverage per meal test
Study: NCT02333942

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: A noninvasive device to detect dementia utilizing headset and sensors

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: A noninvasive device to detect dementia utilizing headset and sensors

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: A noninvasive device to detect dementia utilizing headset and sensors

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: A noninvasive device to detect dementia utilizing headset and sensors
Study: NCT01977495

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive: Fixed Lottery
Description: Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive: Fixed Lottery
Description: Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
Study: NCT00129389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Arm A: FAC Arm B: FAC-wP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Arm A: FAC Arm B: FAC-wP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Arm A: FAC Arm B: FAC-wP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Arm A: FAC Arm B: FAC-wP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Arm A: FAC Arm B: FAC-wP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arm A: FAC Arm B: FAC-wP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Arm B: FAC-wP
Study: NCT01859338

Intervention type: RADIATION
Intervention: cone-beam computed tomography
Description: Undergo CBCT

Intervention type: RADIATION
Intervention: magnetic resonance imaging
Description: Undergo MRI

Intervention type: RADIATION
Intervention: computed tomography
Description: Undergo fan beam computed tomography
Study: NCT01101633

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alginate
Description: a 330 ml alginate beverage per meal test

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a 500 ml placebo beverage per meal test

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a 330 ml placebo beverage per meal test
Study: NCT02700009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted CBT (CCBT)
Description: Computer-assisted psychotherapy for depression using a computer program plus clinician support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Ordinary treatment for depression in primary care setting
Study: NCT03214471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
Study: NCT04451720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous (SC) injection
Study: NCT00991211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Comparison of Bendamustine + Rituximab with CHOP + Rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemotherapy CHOP + Ritiximab
Description: Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
Study: NCT02112565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNR inhibitor COH29
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04530227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Camrelizumab
Description: PD-1
Study: NCT04451720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study: NCT04530227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: chemotherapy
Study: NCT03762187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: Individuals select important values and then write about why that value is important to them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive living counseling
Description: Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive living counseling
Description: Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
Study: NCT02574273

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Group / Treatment As Usual
Description: The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
Study: NCT03633110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-009 Adjuvanted Vaccine
Description: GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-009 Adjuvanted Vaccine
Description: GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
Study: NCT02673463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical to spironolactone, once daily
Study: NCT01151371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon B contact lens
Description: Silicone Hydrogel Daily Disposable Contact Lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A contact lens
Description: Conventional Hydrogel Daily Disposable Contact Lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B contact lens
Description: Silicone Hydrogel Monthly Replacement Contact Lenses
Study: NCT04329910

Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only

Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only
Study: NCT00747084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
Study: NCT02555176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Follow a low-carbohydrate diet